Encarnacion Sastre nackt

Admin18.08.2021

EncarnaciÃ³n Sastre

PMID: 33711671 Free PMC article.

tanlines

8209

Admin05.09.2021

EncarnaciÃ³n Sastre

2 Hospital Universitario Central de Asturias, Medical Oncology Department, Oviedo, Spain.

voyeur

73010

Admin08.08.2021

EncarnaciÃ³n Sastre

Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A.

fetish

3701

Admin24.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

fisting

7006

Admin04.09.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Competing interests: EA has done consulting or advisory roles for Amgen, Bayer, Celgene, Merck, Roche and Sanofi.

bbw

3801

Admin27.06.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

BG has done consulting or advisory roles for Celgene and Sanofi, received research funding from Amgen, Celgene, Erytech Pharma, Gilead Sciences, Lilly, Parexel, and Sanofi, and travel, accommodation, and expenses from Amgen, Celgene, Roche, Sanofi and Servier.

insertion

8609

Admin03.09.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ